辛伐他汀对急性冠状动脉综合征患者血清MMP-1、MMP-9及TIMP-1的作用

The Effect of Simvastatin on Serum Level of Matrix Metalloprotease-1,Matrix Metalloprotease-9 and Tissue Inhibitors of Matrix Metalloproteinase-1 in Patients with Acute Coronary Syndromes

目的 探讨急性冠状动脉综合征 (ACS)辛伐他汀与动脉粥样斑块稳定的可能机制。方法 选择稳定型心绞痛 (SAP)患者 30例健康人作为对照。随机将ACS患者分成辛伐他汀治疗组 (30例 )及常规治疗组 (30例 ) ,比较各组患者血清MMP 1、MMP 9,TIMP 1水平变化。结果 SAP、ACS、健康对照三组之间MMP 1、MMP 9和TIMP 1水平比较差异有统计学意义 ,辛伐他汀治疗组与常规治疗组治疗后血清MMP 1、MMP 9和TIMP 1水平相比差异有统计学意义。结论 辛伐他汀可降低ACS患者血清MMP 1、MMP 9水平 ,升高TIMP 1水平 。

Objective To observe the effect of simvastatin of serun levels of matrix metalloprotease-9 (MMP-1?MMP-9) and tissue inhibitors of matris metalloproteinase-1 (TIMP-1) in patients with acute coronary syndromes(ACS).Methods 90 patients with coronary heart disease were studied. Among them, there were 30 patients with stable angina pectoris(SAP) and 60 patients with ACS. At the same time, 30 cases of age matched healthy individuals were selected as a control.54 patients with ACS were randomly divided into two groups:Simvastatin treatment group and regular treatment group. The serum level of MMP-1?MMP-9and TIMP-1 were compared among all groups.Results There was a significant difference in serum level of MMP-1?MMP-9 and TIMP-1 among SAP group, ACS group and control group.The serum level of MMP-1?MMP-9 and TIMP-1 were different between simanastatin treatment group and regular treatment group after treatment.Conclusions Plaque disruption may be related to the increased serum level of MMP-1?MMP-9 and the decreased serum level of TIMP-1. Simavastatin can decrease serum level of MMP-1?MMP-9 and increase serum level of TIMP-1 in patients with ACS,and int may have a beneficial effect on steadying the plaque.